Abstract: Objective To observe the effect of elemene oral breast combined with docetaxel+oxaliplatin (DO) chemotherapy regimen on serum levels of miR-203 and miR-21 in patients with advanced esophageal cancer. Methods A total of 92 patients with advanced esophageal cancer who were treated in Nanyang Zhang Zhongjing Hospital from January 2017 to February 2019 were selected and divided into two groups according to the random number table method, with 46 cases in each group. The routine group was treated with DO, chemotherapy regimen and the study group was treated with elemene oral breast on the basis of the routine group. The objective response rate (ORR), disease control rate (DCR), immune function, serum tumor markers, serum levels of miR-203, miR-21 and changes of long-term survival were compared between the two groups. Results The ORR of the study group was 60.86%, which was higher than that of the routine group (39.13%, P<0.05); the DCR of the study group was 76.09%, which was higher than that of the routine group (56.52%, P<0.05). After treatment, the levels of NK and CD4⁺ in the study group were higher than those in the routine group, the level of CD8⁺ was lower than that in the routine group ( P<0.05). After treatment, the CEA, SCC, TSGF, NSE indexes in the study group were lower than those in the routine group ( P<0.05). After treatment,the level of miR-21 in the study group was higher than that in the routine group, and the level of miR-21 was lower than that in the routine group ( P<0.05). The two-year follow-up showed that the 1-year survival rate and the 2-year survival rate of the study group were higher than those of the routine group ( P<0.05). Conclusion Elemene oral breast combined with DO chemotherapy regimen in treatment of advanced esophageal cancer can effectively regulate the immune function of patients and the expression of miR-203 and miR-21, and prolong the survival period with significant effect.

Key words: esophageal cancer, elemene oral emulsion, DO chemotherapy regimen, immune function

摘要： 目的 探究榄香烯口服乳联合多西紫杉醇+奥沙利铂（DO）化疗方案对食管癌患者血清miR-203、miR-21水平的影响。方法 选取南阳张仲景医院2017年1月~2019年2月收治的晚期食管癌患者92例,采用随机数字表法分组,各46例。常规组给予DO化疗方案,研究组在此基础上联合榄香烯口服乳。对比2组客观缓解率（ORR）、疾病控制率（DCR）、免疫功能、血清肿瘤标志物、血清miR-203、miR-21水平及远期生存率变化情况。结果 研究组ORR为60.86%,高于常规组的39.13%（P<0.05）;研究组DCR为76.09%,高于常规组的56.52%（P<0.05）;治疗后,研究组NK、CD4⁺高于常规组,CD8⁺低于常规组（P<0.05）;治疗后2组CEA、SCC、TSGF、NSE比较,研究组低于常规组（P<0.05）;研究组治疗后miR-203高于常规组,miR-21低于常规组（P<0.05）;随访2年显示,研究组1年生存率、2年生存率高于对照组（P<0.05）。结论 榄香烯口服乳联合DO化疗方案治疗晚期食管癌可有效调节免疫功能,调控miR-203、miR-21表达,延长生存期限,效果显著。

关键词: 食管癌, 榄香烯口服乳, 化疗, 免疫功能